keyword
https://read.qxmd.com/read/38656575/staffing-and-antipsychotic-medication-use-in-nursing-homes-and-neighborhood-deprivation
#1
JOURNAL ARTICLE
Jasmine L Travers, Erinn M Hade, Steven Friedman, Aasha Raval, Kimberly Hadson, Jason R Falvey
IMPORTANCE: Inappropriate use of antipsychotic medications in nursing homes is a growing public health concern. Residents exposed to higher levels of socioeconomic deprivation in the area around a nursing home may be currently exposed, or have a long history of exposure, to more noise pollution, higher crime rates, and have less opportunities to safely go outside the facility, which may contribute to psychological stress and increased risk of receiving antipsychotic medications inappropriately...
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38654553/the-trace-amine-associated-receptor-1-agonists-non-dopaminergic-antipsychotics-or-covert-modulators-of-d2-receptors
#2
JOURNAL ARTICLE
Gavin P Reynolds
A major effort of the pharmaceutical industry has been to identify and market drug treatments that are effective in ameliorating the symptoms of psychotic illness but without the limitations of the current treatments acting at dopamine D2 receptors. These limitations include the induction of a range of adverse effects, the inadequate treatment response of a substantial proportion of people with schizophrenia, and the generally poor response to negative and cognitive features of the disease. Recently introduced drug treatments have gone some way to avoiding the first of these, with a reduced propensity for weight gain, cardiovascular risk and extrapyramidal motor effects...
April 23, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38653551/beyond-dopamine-novel-strategies-for-schizophrenia-treatment
#3
REVIEW
Paulina Dudzik, Klaudia Lustyk, Karolina Pytka
Despite extensive research efforts aimed at discovering novel antipsychotic compounds, a satisfactory pharmacological strategy for schizophrenia treatment remains elusive. All the currently available drugs act by modulating dopaminergic neurotransmission, leading to insufficient management of the negative and cognitive symptoms of the disorder. Due to these challenges, several attempts have been made to design agents with innovative, non-dopaminergic mechanisms of action. Consequently, a number of promising compounds are currently progressing through phases 2 and 3 of clinical trials...
April 23, 2024: Medicinal Research Reviews
https://read.qxmd.com/read/38652474/psychotropic-medication-prescribing-for-children-and-adolescents-after-the-onset-of-the-covid-19-pandemic
#4
JOURNAL ARTICLE
Zaba Valtuille, Eric Acquaviva, Vincent Trebossen, Naim Ouldali, Aurelie Bourmaud, Stéphane Sclison, Alexandre Gomez, Alexis Revet, Hugo Peyre, Richard Delorme, Florentia Kaguelidou
IMPORTANCE: Numerous studies have provided evidence for the negative associations of the COVID-19 pandemic with mental health, but data on the use of psychotropic medication in children and adolescents after the onset of the COVID-19 pandemic are lacking. OBJECTIVE: To assess the rates and trends of psychotropic medication prescribing before and over the 2 years after the onset of the COVID-19 pandemic in children and adolescents in France. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used nationwide interrupted time-series analysis of outpatient drug dispensing data from the IQVIA X-ponent database...
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38652060/the-role-of-psychosis-and-clozapine-load-in-excessive-checking-in-treatment-resistant-schizophrenia-longitudinal-observational-study
#5
JOURNAL ARTICLE
Emilio Fernandez-Egea, Shanquan Chen, Estela Sangüesa, Patricia Gassó, Marjan Biria, James Plaistow, Isaac Jarratt-Barnham, Nuria Segarra, Sergi Mas, Maria-Pilar Ribate, Cristina B García, Naomi A Fineberg, Yulia Worbe, Rudolf N Cardinal, Trevor W Robbins
BACKGROUND: A significant proportion of people with clozapine-treated schizophrenia develop 'checking' compulsions, a phenomenon yet to be understood. AIMS: To use habit formation models developed in cognitive neuroscience to investigate the dynamic interplay between psychosis, clozapine dose and obsessive-compulsive symptoms (OCS). METHOD: Using the anonymised electronic records of a cohort of clozapine-treated patients, including longitudinal assessments of OCS and psychosis, we performed longitudinal multi-level mediation and multi-level moderation analyses to explore associations of psychosis with obsessiveness and excessive checking...
May 2024: British Journal of Psychiatry
https://read.qxmd.com/read/38635216/demographics-and-clinical-characteristics-of-patients-of-prescribing-psychologists-psychiatrists-and-primary-care-physicians
#6
JOURNAL ARTICLE
Phillip M Hughes, Joshua D Niznik, Robert E McGrath, Casey R Tak, Robert B Christian, Betsy L Sleath, Kathleen C Thomas
To describe the characteristics of patients receiving psychotropic medication from prescribing psychologists, psychiatrists, and primary care physicians. This descriptive study was conducted using private insurance claims of patients from New Mexico and Louisiana receiving psychotropic medications (anticonvulsants, antidepressants, antipsychotics, hypotensive agents, anxiolytics/sedatives/hypnotics, and stimulants) from 2004 to 2021 ( N = 307,478). Patient characteristics were captured during the 6 months prior to their first psychotropic medication using administrative information, diagnosis and procedure codes, and medication data...
April 18, 2024: American Psychologist
https://read.qxmd.com/read/38634616/trajectory-of-the-body-mass-index-of-children-and-adolescents-attending-a-reference-mental-health-center
#7
JOURNAL ARTICLE
Juliana Echeveste-Navarrete, Patricia Zavaleta-Ramírez, Maria Fernanda Castilla-Peon
OBJECTIVES: The primary objective was to describe the standardized body mass index (z-BMI) trajectory of children and adolescents admitted to a psychiatric reference center in Mexico City according to their diagnosis and medication use. The secondary objective was to compare z-BMI between antipsychotic users and non-users. METHODS: This is a retrospective cohort study. The psychiatric diagnosis, prescribed medications, serial heights, and weights were collected from the medical records...
April 19, 2024: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://read.qxmd.com/read/38627211/thirst-and-drugs-a-study-in-the-world-health-organization-s-pharmacovigilance-database
#8
JOURNAL ARTICLE
Jean-Louis Montastruc
Thirst is a complex physiological compensatory mechanism but could also be associated with drugs. This association was poorly investigated previously. Using the WHO global pharmacovigilance database, Vigibase®, disproportionality analyses potential associations between exposure to drugs and thirst reports were performed. All reports of thirst in adults between 01/01/2000 and 31/12/2023 were included. Results are expressed as reporting odds ratio (ROR). Analysis of the 3186 reports of thirst (978 'serious') allowed, first, to confirm the association between thirst and exposure to vasopressin antagonists (tolvaptan), lithium, gliflozins (dapagliflozin, empagliflozin), pregabalin and antimuscarinic drugs (glycopyronium, oxybutynin, tiotropium)...
April 16, 2024: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/38627071/augmentation-strategies-for-partial-or-non-responders-to-clozapine-in-patients-with-schizophrenia-a-bayesian-network-meta-analysis-of-randomized-controlled-trials
#9
REVIEW
Archana Mishra, Rituparna Maiti, Biswa Ranjan Mishra, Anand Srinivasan
Clozapine is the only approved drug for treatment-resistant schizophrenia, but the response to the drug is often inadequate. Augmentation with other antipsychotics, anticonvulsants, and antidepressants is recommended for such patients, but there is a lack of evidence regarding the most effective therapy. This network meta-analysis was conducted to evaluate the efficacy of pharmacological agents used in the augmentation strategies in patients who were partial/ non-responders to clozapine. Relevant data were extracted from 30 randomized controlled trials through searches of electronic databases (MEDLINE/PubMed, Embase, Cochrane, clinical trial registries)...
May 31, 2024: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://read.qxmd.com/read/38595149/central-neuromodulators-in-irritable-bowel-syndrome-why-how-and-when
#10
JOURNAL ARTICLE
Ignacio Hanna-Jairala, Douglas A Drossman
Irritable bowel syndrome are responsive to treatments using central neuromodulators. Central neuromodulators work by enhancing the synaptic transmission of 5-hydroxytryptamine, noradrenalin and dopamine, achieving a slower regulation or desensitization of their postsynaptic receptors. Central neuromodulators act on receptors along the brain-gut axis, so they are useful in treating psychiatric comorbidities, modifying gut motility, improving central downregulation of visceral signals and enhancing neurogenesis in patients with IBS...
April 9, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38584984/a-study-of-hypertension-and-related-biophysical-and-health-related-lifestyle-behaviors-in-patients-suffering-from-schizophrenia
#11
JOURNAL ARTICLE
Akhilesh Sharma, Devendra Singh Basera, Vikas Suri, Shubh Mohan Singh
BACKGROUND: Schizophrenia is a life-shortening disease. The standardized mortality ratio has been higher than that of the general population, and it has doubled what it was 3-4 decades ago. This rise is mostly attributed to the increased cardiovascular risk associated with high second-generation antipsychotic (SGA) use. Evidence from the first-generation antipsychotic (FGA) era shows a lower prevalence of hypertension (HTN) but data regarding SGAs is scarce. PURPOSE: The purpose of the study was to assess the prevalence of HTN and related factors using standardized methodology in patients with schizophrenia on treatment with SGAs...
January 2024: Annals of Neurosciences
https://read.qxmd.com/read/38581686/comparison-of-polypharmacy-and-potentially-inappropriate-medication-use-in-older-adults-with-and-without-dementia-receiving-residential-medication-management-reviews
#12
JOURNAL ARTICLE
Mouna J Sawan, Alexander Clough, Jodie Hillen, Natalie Soulsby, Danijela Gnjidic
OBJECTIVES: Among residents who had a residential medication management review (RMMR), there is a lack of studies assessing exposure to polypharmacy and potentially inappropriate medications (PIMs) in people with dementia. This study compared the exposure to polypharmacy and PIMs in residents with dementia and without dementia receiving RMMR. METHODS: A retrospective analysis was performed using data of 16,261 residents living in 343 Australian residential aged care facilities who had an RMMR in 2019...
April 6, 2024: Australasian Journal on Ageing
https://read.qxmd.com/read/38578473/treatment-of-hyperprolactinemia-in-women-a-position-statement-from-the-brazilian-federation-of-gynecology-and-obstetrics-associations-febrasgo-and-the-brazilian-society-of-endocrinology-and-metabolism-sbem
#13
JOURNAL ARTICLE
Cristina Laguna Benetti-Pinto, Andrea Prestes Nácul, Ana Carolina Japur de Sá Rosa-E-Silva, Gustavo Arantes Rosa Maciel, Vania Dos Santos Nunes Nogueira, Paula Condé Lamparelli Elias, Manoel Martins, Leandro Kasuki, Heraldo Mendes Garmes, Andrea Glezer
Dopamine agonists are the first line of treatment for patients with symptomatic hyperprolactinemia due to prolactinomas and in those with idiopathic hyperprolactinemia. Treatment with these agents is effective in 80%-90% of the cases. Infertility treatment of patients with hyperprolactinemia is also carried out with dopamine agonists, aiming for the normalization of prolactin levels. The risk of symptomatic growth of prolactinomas during pregnancy is dependent on the tumor's size, duration of previous treatments, and prolactin levels...
April 5, 2024: Archives of Endocrinology and Metabolism
https://read.qxmd.com/read/38576166/antipsychotic-drugs-in-first-episode-psychosis-a-target-trial-emulation-in-the-fep-causal-collaboration
#14
JOURNAL ARTICLE
Alejandro G Szmulewicz, Gonzalo Martínez-Alés, Roger Logan, Maria Ferrara, Christian Kelly, Diane Fredrikson, Juan Gago, Sarah Conderino, Covadonga M Díaz-Caneja, Joaquín Galvañ, Lorna Thorpe, Vinod Srihari, Lakshmi Yatham, Deepak K Sarpal, Ann K Shinn, Celso Arango, Dost Öngür, Miguel A Hernán, On Behalf Of The Fep-Causal Collaboration
Good adherence to antipsychotic therapy helps prevent relapses in First Episode Psychosis (FEP). We used data from the FEP-CAUSAL Collaboration, an international consortium of observational cohorts to emulate a target trial comparing antipsychotics with treatment discontinuation as the primary outcome. Other outcomes included all-cause hospitalization. We benchmarked our results to estimates from EUFEST, a randomized trial conducted in the 2000s. We included 1097 patients with a psychotic disorder and less than 2 years since psychosis onset...
April 3, 2024: American Journal of Epidemiology
https://read.qxmd.com/read/38573558/citalopram-an-antipsychotic-agent-induces-g1-g0-phase-cell-cycle-arrest-and-promotes-apoptosis-in-human-laryngeal-carcinoma-hep-2-cells
#15
JOURNAL ARTICLE
Mohammed Salama, Abeer Ali, Fawziya A R Ibrahim, Seham Elabd
Human laryngeal squamous carcinoma (LSCC) is a common malignant tumor in the head and neck. Despite the recently developed therapies for the treatment of LSCC, patients' overall survival rate still did not enhance remarkably; this highlights the need to formulate alternative strategies to develop novel treatments. The antitumor effects of antidepressant drugs such as citalopram have been reported on several cancer cells; however, they have yet to be investigated against LSCC. The current study was directed to explore the possible antitumor effects of citalopram on human laryngeal carcinoma cell lines (HEP-2)...
April 4, 2024: Medical Oncology
https://read.qxmd.com/read/38563302/assessing-regional-intracortical-myelination-in-schizophrenia-spectrum-and-bipolar-disorders-using-the-optimized-t1w-t2w-ratio
#16
JOURNAL ARTICLE
Kjetil Nordbø Jørgensen, Stener Nerland, Nora Berz Slapø, Linn B Norbom, Lynn Mørch-Johnsen, Laura Anne Wortinger, Claudia Barth, Dimitrios Andreou, Ivan I Maximov, Oliver M Geier, Ole A Andreassen, Erik G Jönsson, Ingrid Agartz
BACKGROUND: Dysmyelination could be part of the pathophysiology of schizophrenia spectrum (SCZ) and bipolar disorders (BPD), yet few studies have examined myelination of the cerebral cortex. The ratio of T1- and T2-weighted magnetic resonance images (MRI) correlates with intracortical myelin. We investigated the T1w/T2w-ratio and its age trajectories in patients and healthy controls (CTR) and explored associations with antipsychotic medication use and psychotic symptoms. METHODS: Patients with SCZ ( n = 64; mean age = 30...
April 2, 2024: Psychological Medicine
https://read.qxmd.com/read/38561588/quetiapine-versus-haloperidol-in-the-management-of-hyperactive-delirium-randomized-controlled-trial
#17
JOURNAL ARTICLE
Tamer Zakhary, Islam Ahmed, Ibrahim Luttfi, Mina Montasser
BACKGROUND: In the population of patients in the intensive care unit (ICU), most studies compared the use of atypical antipsychotics, such as quetiapine, with the use of traditional haloperidol in patients with delirium of various forms and etiologies. The role of such agents in patients with hyperactive delirium is not fully understood. This study compares the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on the Delirium Rating Scale-Revised-98 (DRS-R-98), length of stay in the ICU, and mortality in critically ill patients...
April 1, 2024: Neurocritical Care
https://read.qxmd.com/read/38561326/observational-evidence-linking-psychotropic-medicines-to-the-dispensing-of-opioid-agents-in-later-life
#18
JOURNAL ARTICLE
Osvaldo P Almeida, Amy Page, Frank M Sanfilippo, David B Preen, Christopher Etherton-Beer
BACKGROUND: The use of opioid medicines is common in developed countries, particularly among older adults and those with mental health disorders. It is unclear if the association between mental disorders and opioid medicines is causal, or is due to reverse causality or confounding. METHODS: We used a 10% random sample of the Australian Pharmaceutical Benefits Scheme (years 2012-2022) to examine the cross-sectional, case-control and longitudinal association between the dispensing of antidepressants, anxiolytics, hypnotics, antipsychotics and lithium, and opioid medicines...
April 1, 2024: Psychogeriatrics: the Official Journal of the Japanese Psychogeriatric Society
https://read.qxmd.com/read/38551306/kardiamobile-6l-for-measuring-qt-interval-in-people-having-antipsychotic-medication-to-inform-early-value-assessment-a-systematic-review
#19
Marie Westwood, Nigel Armstrong, Pawel Posadzki, Caro Noake
BACKGROUND: The indication for this assessment is the use of the KardiaMobile six-lead electrocardiogram device for the assessment of QT interval-based cardiac risk in service users prior to the initiation of, or for the monitoring of, antipsychotic medications, which are associated with an established risk of QT interval prolongation. OBJECTIVES: To provide an early value assessment of whether KardiaMobile six-lead has the potential to provide an effective and safe alternative to 12-lead electrocardiogram for initial assessment and monitoring of QT interval-based cardiac risk in people taking antipsychotic medications...
March 2024: Health Technology Assessment: HTA
https://read.qxmd.com/read/38533552/taar1-agonist-ulotaront-delays-gastric-emptying-of-solids-in-patients-with-schizophrenia-and-concurrent-metabolic-syndrome-with-prediabetes
#20
JOURNAL ARTICLE
Snežana Milanović, Nina Dedic, Robert Lew, Duane Burton, Kenneth S Koblan, Michael Camilleri, Seth C Hopkins
BACKGROUND: Metabolic syndrome (MetS), which can be induced or exacerbated by the current class of antipsychotic drugs, is highly prevalent in patients with schizophrenia and presents significant challenges to lifetime disease management. Supported by initial clinical results, trace amine-associated receptor 1 (TAAR1) agonists have emerged as potential novel treatments for schizophrenia. Notably, non-clinical studies have also shown weight-lowering and glucoregulatory effects of TAAR1 agonists, including the investigational agent ulotaront...
March 27, 2024: Diabetes, Obesity & Metabolism
keyword
keyword
43995
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.